Most treatment guidelines for acne are based on clinical severity. Our objective was to expand that approach to one that also comprised individualized patient features: a case-based approach.
Methods:
An expert panel of Canadian dermatologists was established to develop demographic and clinical features considered to be particularly important in acne treatment selection. A nominal group consensus process was used for inclusion of features and corresponding appropriate treatments.
Results:
Consensus was achieved on the following statements: follicular epithelial dysfunction contributes to acne pathogenesis; inflammation from underlying disease(s) or prior treatment may impact further patient management; management focusing on specific patient features and on addressing psychosocial factors, including impact on quality of life, may improve treatment adherence and outcomes; and case-based scenarios are a practical approach to illustrate the effect of these factors. To address the latter, eight case profiles were developed.
Conclusions:
Management of acne should be based on multifactorial considerations beyond clinically determined acne severity and should include patient-reported impact, gender, skin sensitivity (including preexisting dermatoses), and phototype.
Get full access to this article
View all access options for this article.
References
1.
NastADrenoBBettoliV. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol2012;26Suppl 1:1–29.
JamesWD. Acne. N Engl J Med2005;352:1463–72, doi:10.1056/NEJMcp033487.
4.
GollnickH. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs2003;63:1579–96, doi:10.2165/00003495-200363150-00005.
5.
PerkinsAChengCHillebrandG. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol2010;25:1054–60, doi:10.1111/j.1468-3083.2010.03919.x.
6.
KurokawaIDanbyFWJuQ. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol2009;18:821–32, doi:10.1111/j.1600-0625.2009.00890.x.
7.
TanJKTangJFungK. Development and validation of a comprehensive acne severity scale. J Cutan Med Surg2007;11:211–6.
8.
JeremyAHHollandDBRobertsSG. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol2003;121:20–7, doi:10.1046/j.1523-1747.2003.12321.x.
9.
GouldenVStablesGICunliffeWJ. Prevalence of facial acne in adults. J Am Acad Dermatol1999;41:577–80.
10.
DrénoBPoliF. Epidemiology of acne. Dermatology2003;206:7–10, doi:10.1159/000067817.
11.
CordainLLindebergSHurtadoM. Acne vulgaris: a disease of Western civilization. Arch Dermatol2002;138:1584–90, doi:10.1001/archderm.138.12.1584.
12.
GollnickHCunliffeWBersonD. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol2003;49(1 Suppl):S1–37, doi:10.1067/mjd.2003.618.
13.
IngramJRGrindlayDJWilliamsHC. Management of acne vulgaris: an evidence-based update. Clin Exp Dermatol2010;35:351–4, doi:10.1111/j.1365-2230.2009.03683.x.
14.
StraussJSKrowchukDPLeydenJJ. Guidelines of care for acne vulgaris management. J Am Acad Dermatol2007;56:651–63, doi:10.1016/j.jaad.2006.08.048.
15.
HeraneMIAndoI. Acne in infancy and acne genetics. Dermatology2003;206:24–8, doi:10.1159/000067819.
16.
VowelsBRYangSLeydenJJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun1995;63:3158–65.
17.
HollandDBJeremyAH. The role of inflammation in the pathogenesis of acne and acne scarring. Semin Cutan Med Surg2005;24:79–83, doi:10.1016/j.sder.2005.03.004.
18.
KapetanovicRCavaillonJM. Early events in innate immunity in the recognition of microbial pathogens. Expert Opin Biol Ther2007;7:907–18, doi:10.1517/14712598.7.6.907.
19.
JugeauSTenaudIKnolAC. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol2005;153:1105–13, doi:10.1111/j.1365-2133.2005.06933.x.
20.
KangSChoSChungJH. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol2005;166:1691–9, doi:10.1016/S0002-9440(10)62479-0.
21.
KimJOchoaMTKrutzikSR. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol2002;169:1535–41.
LeydenJJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol2003;49(3 Suppl): S200–10, doi:10.1067/S0190-9622(03)01154-X.
24.
TanJKBalagurusamyMFungK. Effect of quality of life impact and clinical severity on adherence to topical acne treatment. J Cutan Med Surg2009;13:204–8.
25.
LeeIAMaibachHI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol2006;7:231–6, doi:10.2165/00128071-200607040-00004.
26.
BucksDAWPillaiRSMcCall-PerezF. Advances in formulation technologies: creating highly effective and well-tolerated topical dermatologicals. Skin Aging2010;Suppl:4–6.
27.
YentzerBAAdeRAFountainJM. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis2010;86:103–8.
28.
YentzerBABaldwinHShalitaA. Optimizing patient adherence: update on combination acne therapy – teens and beyond. J Drugs Dermatol2010;9:s92–5.
29.
FeldmanSRChenDM. How patients experience and manage dryness and irritation from acne treatment. J Drugs Dermatol2011;10:605–8.
30.
BucksDSarpotdarPYuK. The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel with minimal irritation and enhanced bioavailability. J Drugs Dermatol2009;8:634–8.
31.
DrénoBThiboutotDGollnickH. Global Alliance to Improve Outcomes in Acne. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol2010;49:448–56, doi:10.1111/j.1365-4632.2010.04416.x.
32.
DraelosZDCallenderVYoungCSunilSD. The effect of vehicle formulation on acne medication tolerability. Cutis2008;82:281–4.
RaimerSMaloneyJMBourcierM. United States/Canada Dapsone Gel Study Group. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis2008;81:171–8.
35.
PietteWWTaylorSPariserD. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol2008;144:1564–70, doi:10.1001/archdermatol.2008.518.
36.
FitzpatrickTB. Soleil et peau. J Med Esthet1975;2:330–4.
37.
KooJ. How do you foster medication adherence for better acne vulgaris management?Skinmed2003; 2:229–33, doi:10.1111/j.1540-9740.2003.02037.x.
38.
ChengCEIrwinBMaurielloD. Self-reported acne severity, treatment, and belief patterns across multiple racial and ethnic groups in adolescent students. Pediatr Dermatol2010;27:446–52, doi:10.1111/j.1525-1470.2010.01286.x.
39.
DrénoBBettoliVOchsendorfF. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol2006;16:565–71.
40.
SagranskyMYentzerBAFeldmanSR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother2009;10:2555–62, doi:10.1517/14656560903277228.
41.
ThiboutotDMWeissJBuckoA. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol2007;57:791–9, doi:10.1016/j.jaad.2007.06.006.
